The International Conference on Clinical Biostatistics and Epidemiology includes keynote presentations, oral talks, poster presentations, and exhibitions. The conference will bring together healthcare professionals across all fields related to epidemiology, biostatistics and public health globally and will cover broad subject matter expertise in biostatistics, healthcare epidemiology, long-term care, research methods, clinical microbiology, patient safety and quality, implementation science, and networking and communication.
With the scale up of high-impact interventions to address high infectious disease prevalence comes with it an ever-increasing volume of health care waste. This increase in generated waste poses risk for health workers, patients, communities, and the environment. AIDSFree assessed the suitable waste treatment technologies, developed equipment specifications, and established operating parameters for health care waste treatment.
The recent Ebola virus outbreak in West Africa clearly demonstrated the critical role of laboratory systems and networks in responding to epidemics. Because of the huge challenges in establishing functional laboratories at all tiers of health systems in developing countries, strengthening specimen referral networks is critical. In this review article, we propose a platform strategy for developing specimen referral networks based on 2 models: centralized and decentralized laboratory specimen referral networks.
TB partners, patients ask: How does a bacterium responsible for nearly a third of drug-resistance deaths not make list of R&D priority pathogens?
Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics
The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments. To date, the selection of pathogens for R&D activities has been largely guided by small and large pharmaceutical companies according to a variety of parameters, such as perceived/unmet medical need, pressure of investors, market size, scientific discovery potential, and availability of specific technologies.
Editor’s Note: This post reflects on a speech on pandemic preparedness Dr. Fauci gave on January 10, 2017 in Washington, DC, hosted by The Center for Global Health Science and Security at Georgetown University Medical Center, the Harvard Global Health Institute, and Health Affairs.
U.S. Government Roles in Control of Global Tuberculosis: Opportunities for Strengthening Program Effectiveness
Over the first 15 years of this century, as efforts against the “big three” global infectious diseases — HIV, malaria and tuberculosis — accelerated, the numbers of new HIV infections dropped by 32 percent, and the number of deaths caused by the virus declined by 31 percent. Malaria infections dropped by 18 percent, and deaths from that disease went down by 48 percent.